NEW BRUNSWICK, NJ — December 2025 — Johnson & Johnson announced new one-year results showing that its intravesical gemcitabine delivery system, INLEXZO™, achieved a 74% disease-free survival rate in patients with BCG-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer (NMIBC). The findings, emerging from the Phase 3 SunRISe-1 study, underscore the therapeutic potential of INLEXZO as an innovative office-administered bladder-preserving treatment for a population with extremely limited options.

Science Significance

The results reinforce the scientific importance of localized, intravesical chemotherapeutic delivery, which allows gemcitabine to remain in contact with bladder tissue for extended periods through a sustained-release hydrogel system. The 74% disease-free survival (DFS) at 12 months represents a substantial improvement in a setting historically characterized by rapid recurrence and progression. These findings validate the pharmacokinetic and pharmacodynamic advantages of targeted intravesical administration, demonstrating how controlled local exposure can enhance therapeutic effect while minimizing systemic toxicity. INLEXZO’s performance supports continued development of next-generation, organ-preserving drug-delivery platforms designed for hard-to-treat urothelial cancers.

Regulatory Significance

The strong clinical outcomes have notable regulatory implications for a high-risk population defined by strict FDA and EMA guidance on BCG-unresponsive disease. Treatments in this category require demonstration of clinically meaningful responses with durable benefit, bladder preservation impact, and manageable safety. INLEXZO’s data strengthen its position under regulatory pathways for localized chemotherapeutic delivery, supporting evidence packages related to quality, safety, clinical efficacy, and real-world feasibility. As post-approval commitments and confirmatory evidence obligations expand under global oncology regulations, the study’s results may streamline regulatory maintenance, pharmacovigilance strategies, and labeling optimization for INLEXZO across international markets.

Business Significance

The performance of INLEXZO in high-risk NMIBC strengthens Johnson & Johnson’s strategic position within the urologic oncology franchise. With bladder cancer representing the sixth most common cancer in the United States, and BCG shortages continuing to affect global healthcare systems, INLEXZO offers a commercially significant solution with differentiated clinical value. The strong DFS outcomes may accelerate market penetration, hospital adoption, payer engagement, and international expansion, particularly as intravesical administration can be performed in outpatient urology practices without new infrastructure. The SunRISe program’s continued data releases will further influence commercial trajectory and long-term revenue potential.

Patients’ Significance

For patients with BCG-unresponsive, high-risk NMIBC, current choices often narrow to radical cystectomy — a major surgery that removes the bladder and significantly affects quality of life. INLEXZO provides a bladder-preserving alternative supported by durable clinical benefit, enabling patients to avoid or delay radical surgery. The 74% one-year DFS demonstrates meaningful disease control, offering reassurance to patients seeking effective, less invasive treatments. Its office-based administration also reduces patient burden, enhancing accessibility, convenience, and continuity of care.

Policy Significance

The clinical performance of INLEXZO aligns with emerging healthcare policy priorities focused on organ preservation, patient-centered oncology care, and expansion of community-based cancer treatment. Policymakers increasingly emphasize alternatives to high-morbidity surgical interventions when effective pharmacologic options exist. INLEXZO’s robust data may support policy shifts toward early adoption of intravesical chemotherapeutic systems, adjustments to reimbursement frameworks, and incorporation into bladder cancer management guidelines. Its outpatient-based administration model also aligns with national strategies emphasizing cost-effective cancer care delivery outside hospital settings.

Johnson & Johnson’s new INLEXZO data represent a major milestone for patients with high-risk NMIBC, demonstrating substantial disease control with a bladder-preserving, office-administered therapy in a population that urgently needs alternatives to radical cystectomy. With strong scientific validation, regulatory relevance, and significant implications for healthcare delivery, INLEXZO stands poised to shift the therapeutic paradigm for BCG-unresponsive bladder cancer and expand access to innovative urologic oncology treatments worldwide.

Source:   Johnson & Johnson press release